Our assessment of p53 by immunoblotting in double-mutant colorectal cancer cell lines demonstrated an increase in p53 upon treatment with alisertib alone and in combination with TAK-733 at both 24 and 72 h in a p53 mutant model, DLD-1. This evidence concerns the gene TP53 and colorectal cancer.